Market Intelligence, Clinical Progress, and High-Purity Reagents for HIF Pathway Modulation and PROTAC Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for VHL drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen (Wild-Type) | VHL Recombinant Protein (Full Length) High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed. |
View VHL Products |
| Antigen (Mutant Panel) | VHL Cancer Mutants (R167Q, W88X, L188V) For selectivity and loss-of-function assays. Theoretical MW confirmed. |
View VHL Products |
| Complex Protein | VHL-ElonginC-ElonginB Complex (VBC) Reconstituted E3 ligase substrate recognition module. Critical for ternary complex assays. |
View VHL Products |
| Gene Delivery | VHL Lentivirus Premade Particles / Promise-ORF Full-length ORF for stable cell line construction in VHL-null backgrounds. |
View VHL Products |
| Benchmark Ab | Anti-VHL Monoclonal Antibody Recombinant positive control; research-grade for IP/Western validation. Sequence Verified. |
View VHL Products |
| Validator | VHL siRNA Set For knockdown verification and specificity controls. |
View VHL Products |
| Related Target: Substrate | HIF1A (HIF-1α) Primary substrate for VHL-mediated ubiquitination assays. |
View HIF1A Products |
| Related Target: Substrate | EPAS1 (HIF-2α) Alternative substrate; critical for ccRCC therapeutic targeting. |
View EPAS1 Products |
| Related Target: E3 Ligase | CRBN Alternative major E3 ligase for PROTAC comparative profiling. |
View CRBN Products |
| Related Target: Complex Partner | TCEB1 (Elongin C) Essential binding partner for VHL E3 complex assembly. |
View TCEB1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| E3 Ligase Complex Stability & Ternary Complex Formation | VHL-ElonginBC Complex available with >95% purity; validated assembly by SEC-MALS; expressed as VBC complex for native conformation. |
| Mutant VHL Selectivity (ccRCC Resistance) | Comprehensive mutant panel (R167Q, W88X, L188V) with Sequence Verified integrity for binding assays. |
| HIF Hydroxylation Dependent Binding | Compatible with PHD-modified substrates; Endotoxin controlled (<1 EU/μg) for sensitive cell assays. |
| Intracellular Target Engagement | Lentivirus delivery system for VHL-null cell line reconstitution (HEK293, 786-O). |
| Lack of Controls | Recombinant Benchmark Antibodies included for precise western blot quantification. |
| False Positives in Degradation | Validating siRNA included for VHL-dependency specificity checks. |
Live VHL R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic landscape surrounding VHL is bifurcating into two strategic vectors: exploiting VHL as an E3 ligase recruiter for targeted protein degradation (TPD) via PROTACs, and directly inhibiting VHL function to stabilize HIF-α for anemia and ischemic indications. As first-generation VHL-recruiting PROTACs enter Phase II trials, the field is pivoting toward molecular glues and differentiated VHL ligands that offer improved physicochemical properties. Simultaneously, the approval of HIF-2α inhibitors (Belzutifan) for VHL disease has renewed interest in upstream VHL modulation as a combinatorial strategy. The race for oral bioavailability, tissue-specific degradation profiles, and novel ternary complex geometries is intensifying among major players.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| VHL-Recruiting PROTACs | Arvinas, C4 Therapeutics, Nurix, Kymera | Metastatic Breast/Prostate Cancer, Oncology | Ternary Complex Validation (Need VHL-ElonginBC complex) |
| VHL Molecular Glues | C4 Therapeutics, Monte Rosa, Various Biotechs | Hematological Malignancies, Solid Tumors | Mutant Selectivity Panel (Need R167Q, W88X mutants) |
| HIF Stabilizers (VHL-HIF inhibitors) | Early Discovery (Academic), Merck, Peloton | Anemia of CKD, Ischemia, Renal Cell Carcinoma | Competition Binding Assay (Need HIF1A/EPAS1 proteins) |
| VHL Gene Therapy | LogicBio, Beam Therapeutics | VHL Disease (Hereditary) | Functional Validation (Need Lentivirus and wild-type protein) |
| Small Molecule Inhibitors (Direct) | Merck, Peloton | Renal Cell Carcinoma | Binding Affinity (Need High-Purity VHL) |